Berinstein, Jeffrey
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Berinstein, Jeffrey sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Berinstein, Jeffrey: 2 sponsored US clinical trials, 2 recruiting.
Berinstein, Jeffrey sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ulcerative Colitis Acute, with 2 trials.
Mid-pack sponsor footprint
Berinstein, Jeffrey is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
NCT07258771
Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
NCT05867329
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
Therapeutic Areas
Where Berinstein, Jeffrey enrollment is open (later-stage tilt)
2 recruiting of 2 indexed (100% open).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Ulcerative Colitis Acute (2 trials), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Berinstein, Jeffrey: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Berinstein, Jeffrey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Berinstein, Jeffrey page
2 registered trials is a research-attention snapshot, not an endorsement of Berinstein, Jeffrey or any single study.
- 2 of Berinstein, Jeffrey's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ulcerative Colitis Acute is the condition Berinstein, Jeffrey studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ulcerative Colitis Acute trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Berinstein, Jeffrey pipeline card: 2 registered trials from official public datasets.Report a data error.